FitLife Brands, Inc. (the “ Company”) is a provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, “ NDS Products”); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the " iSatori Products"); (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals, each acquired as a result of the acquisition of Mimi’s Rock Corp. (“ MRC”) on February 28, 2023 (together, the “ MRC Products"); and (iv) MusclePharm, which was acquired on October 10, 2023 as a result of the acquisition of substantially all of the assets of MusclePharm Corporation (“ MusclePharm”). - 2 - The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 71M | 64M | 53M | - | - | 22M |
| Net Income | 6.8M | 9.0M | 5.3M | 4.4M | 5.4M | 8.8M |
| EPS | $0.68 | $0.46 | $0.27 | $0.45 | $0.57 | $0.97 |
| Free Cash Flow | 8.1M | 9.6M | 4.1M | 4.1M | 4.5M | 5.7M |
| ROIC | 10.1% | 23.2% | 12.7% | 52.8% | 66.1% | 142.9% |
| Gross Margin | 40.7% | 43.6% | 40.7% | - | - | 43.9% |
| Debt/Equity | 0.97 | 0.37 | 0.75 | 0.00 | 0.01 | 0.06 |
| Dividends/Share | $0.00 | - | - | - | - | $0.00 |
| Operating Income | 11M | 13M | 7.6M | 5.7M | 6.2M | 4.4M |
| Operating Margin | 15.1% | 20.3% | 14.3% | - | - | 20.4% |
| ROE | 16.1% | 28.4% | 19.6% | 22.9% | 37.0% | 118.1% |
| Shares Outstanding | 9M | 20M | 20M | 10M | 10M | 9M |
FITLIFE BRANDS, INC. passes 5 of 9 quality checks, suggesting mixed fundamentals.
FITLIFE BRANDS, INC. trades at 13.6x trailing earnings, compared to its 15-year median P/E of 15.4x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 10.7x vs a median of 11.3x. The company's 5-year average ROIC is 59.5% with a gross margin of 42.7%. At current prices, the estimated annualized return to fair value is +25.9%.
FITLIFE BRANDS, INC. (FTLF) has a current P/E ratio of 13.6, compared to its historical median P/E of 15.4. The stock is currently considered Fair based on its historical valuation range.
FITLIFE BRANDS, INC. (FTLF) has a 5-year average return on invested capital (ROIC) of 59.5%. This indicates strong capital allocation and a potential competitive advantage.
FITLIFE BRANDS, INC. (FTLF) has a market capitalization of $87M. It is classified as a small-cap stock.
FITLIFE BRANDS, INC. (FTLF) does not currently pay a regular dividend.
Based on historical P/E analysis, FITLIFE BRANDS, INC. (FTLF) appears fair. The current P/E of 13.6 is 11% below its historical median of 15.4. The estimated fair value CAGR (P/E method) is 8.3%.
FITLIFE BRANDS, INC. (FTLF) operates in the Medicinal Chemicals & Botanical Products industry, within the Healthcare sector.
FITLIFE BRANDS, INC. (FTLF) reported annual revenue of $64 million in its most recent fiscal year, based on SEC EDGAR filings.
FITLIFE BRANDS, INC. (FTLF) has a net profit margin of 13.9%. This is a healthy margin.
FITLIFE BRANDS, INC. (FTLF) generated $10 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
FITLIFE BRANDS, INC. (FTLF) has a debt-to-equity ratio of 0.37. This indicates a conservatively financed balance sheet.
FITLIFE BRANDS, INC. (FTLF) reported earnings per share (EPS) of $0.46 in its most recent fiscal year.
FITLIFE BRANDS, INC. (FTLF) has a return on equity (ROE) of 28.4%. This indicates the company generates strong returns for shareholders.
FITLIFE BRANDS, INC. (FTLF) has a 5-year average gross margin of 42.7%. This indicates decent pricing power.
The Ledger Terminal provides 15 years of financial data for FITLIFE BRANDS, INC. (FTLF), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
FITLIFE BRANDS, INC. (FTLF) has a book value per share of $1.83, based on its most recent annual SEC filing.